drugset / Trial / NCT00000611

Summary

To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).

Timeline

Start
—
Primary completion
2005-03
Completion
—

Outcome

Mixed primary results

paper lower incidence of invasive breast cancer (151 cases, 0·27% per year) compared with placebo (199 cases, 0·35% per year; HR 0·77, 95% CI 0·62-0·95; p=0·02) PMID 22401913 ↗

paper did not result in a statistically significant reduction in invasive breast cancer risk over an 8.1-year average follow-up period. PMID 16467232 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium Small molecule 1000 mg —
Subject Conjugated equine estrogens Unknown 0.625 mg Oral
Subject Vitamin D Other / unclassified 400 iu —
Subject progestins Unknown 2.5 mg —